問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
林宗哲
下載
2019-11-30 - 2026-09-30
Condition/Disease
Test Drug
Participate Sites9Sites
Recruiting9Sites
2020-04-01 - 2025-11-26
Participate Sites7Sites
Not yet recruiting2Sites
Recruiting4Sites
Terminated1Sites
2021-03-01 - 2026-12-30
Participate Sites6Sites
Recruiting6Sites
2022-06-01 - 2026-12-31
Not yet recruiting1Sites
Recruiting5Sites
2018-04-30 - 2020-04-30
Participate Sites2Sites
Recruiting2Sites
2019-04-01 - 2022-12-31
-
Participate Sites8Sites
Recruiting1Sites
Terminated7Sites
2019-12-20 - 2024-08-16
advanced hepatocellular carcinoma (HCC)
1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)
2015-12-10 - 2019-12-31
NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES
(1)Avastin; (2) Erlotinib
Participate Sites3Sites
Recruiting3Sites
non-squamous non-small cell lung cancer
Durvalumab、Tremelimumab
Recruiting8Sites
Division of General Internal Medicine
2018-09-01 - 2022-12-31
Hepatocellular Carcinoma (HCC)
nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞
全部
